Van Eck Associates Corp Novavax Inc Transaction History

Van Eck Associates Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$36.28 - $75.29 $711,741 - $1.48 Million	-19,618 Reduced 15.21%	109,388 $5.63 Million
Q1 2022 May 10, 2022	BUY	$69.73 - $142.9 $765,635 - $1.57 Million	10,980 Added 9.3%	129,006 $9.5 Million
Q4 2021 Jan 26, 2022	BUY	$134.56 - $217.97 $148,150 - $239,984	1,101 Added 0.94%	118,026 $16.9 Million
Q3 2021 Nov 03, 2021	SELL	$177.8 - $270.58 $3.4 Million - $5.18 Million	-19,149 Reduced 14.07%	116,925 $24.2 Million
Q2 2021 Aug 10, 2021	SELL	$121.0 - $257.67 $3.81 Million - $8.12 Million	-31,524 Reduced 18.81%	136,074 $28.9 Million
Q1 2021 May 13, 2021	BUY	$112.98 - $319.93 $6.47 Million - $18.3 Million	57,294 Added 51.94%	167,598 $30.4 Million
Q4 2020 Feb 09, 2021	BUY	$78.74 - $139.5 $2.75 Million - $4.87 Million	34,889 Added 46.26%	110,304 $12.3 Million
Q3 2020 Nov 12, 2020	BUY	$79.44 - $178.51 $5.99 Million - $13.5 Million	75,415 New	75,415 $8.17 Million

287

94.6M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $660M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.